Cargando…

Photoacoustic imaging of integrin-overexpressing tumors using a novel ICG-based contrast agent in mice

PhotoAcoustic Imaging (PAI) is a biomedical imaging modality currently under evaluation in preclinical and clinical settings. In this work, ICG is coupled to an integrin binding vector (ICG-RGD) to combine the good photoacoustic properties of ICG and the favourable α(v)β(3)-binding capabilities of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Capozza, Martina, Blasi, Francesco, Valbusa, Giovanni, Oliva, Paolo, Cabella, Claudia, Buonsanti, Federica, Cordaro, Alessia, Pizzuto, Lorena, Maiocchi, Alessandro, Poggi, Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086215/
https://www.ncbi.nlm.nih.gov/pubmed/30105205
http://dx.doi.org/10.1016/j.pacs.2018.07.007
Descripción
Sumario:PhotoAcoustic Imaging (PAI) is a biomedical imaging modality currently under evaluation in preclinical and clinical settings. In this work, ICG is coupled to an integrin binding vector (ICG-RGD) to combine the good photoacoustic properties of ICG and the favourable α(v)β(3)-binding capabilities of a small RGD cyclic peptidomimetic. ICG-RGD is characterized in terms of physicochemical properties, biodistribution and imaging performance. Tumor uptake was assessed in subcutaneous xenograft mouse models of human glioblastoma (U-87MG, high α(v)β(3) expression) and epidermoid carcinoma (A431, low α(v)β(3) expression). ICG and ICG-RGD showed high PA signal in tumors already after 15 min post-injection. At later time points the signal of ICG rapidly decreased, while ICG-RGD showed sustained uptake in U-87MG but not in A431 tumors, likely due to the integrin-mediated retention of the probe. In conclusion, ICG-RGD is a novel targeted contrast agents for PAI with superior biodistribution, tumor uptake properties and diagnostic value compared to ICG.